JosephMTuscanoMD

Oncology • Sacramento, CA

Hematologic Oncology

Professor, Internal Medicine, UC, Davis School of Medicine

Join to view full profile

Dr. Tuscano is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tuscano's full profile

Already have an account?

Office
4501 X St
Ste 3016
Sacramento, CA 95817
Phone+1 916-734-5981

Fax+1 916-734-0631

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1994 - 1996
National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1992 - 1994
University of California Davis HealthResidency, Internal Medicine, 1989 - 1992
Keck School of Medicine of the University of Southern CaliforniaClass of 1989

Certifications & Licensure

CA State Medical License 1990 - 2025
MD State Medical License 1992 - 1997
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma Start of enrollment: 2007 Dec 01
Terminated
Phase 1
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML Start of enrollment: 2007 Aug 01
Terminated
Phase 3
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma Start of enrollment: 2008 Aug 25
Active, not recruiting
Phase 2
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) Start of enrollment: 2009 Apr 01
Completed
Phase 2
Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2010 Dec 01
Active, not recruiting
Phase 2
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Start of enrollment: 2012 Apr 16
Completed
Phase 1
Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma Start of enrollment: 2013 Jan 14
Completed
Phase 2
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma Start of enrollment: 2012 Nov 19
Completed
Phase 1
Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia Start of enrollment: 2012 Dec 19
Completed
Phase 2
Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Start of enrollment: 2013 Mar 12
Active, not recruiting
Phase 2
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma Start of enrollment: 2013 Oct 01
Completed
Phase 2
Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma Start of enrollment: 2015 Oct 01
Active, not recruiting
Phase 1, Phase 2
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Start of enrollment: 2020 Aug 20
Active, not recruiting
Phase 3
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma Start of enrollment: 2021 Feb 24
Recruiting
Phase 2
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Start of enrollment: 2020 Oct 23
Active, not recruiting
Phase 1
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma Start of enrollment: 2020 Dec 04
Recruiting
Phase 2
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2024 May 20
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

23 citations
Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.
Noriko Satake, Connie P.M. Duong, Sakiko Yoshida, Michael Oestergaard, Cathy Chen
Molecular Medicine. 2016-07-22
247 citations
CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling.
Thomas F. Tedder, Joseph Tuscano, Shinichi Sato, John H. Kehrl
Annual Review of Immunology. 1997-01-01
473 citations
Prospective Evaluation of Cancer Clinical Trial Accrual Patterns: Identifying Potential Barriers to Enrollment
Primo N. Lara, Roger Higdon, Nelson Lim, Karen Kwan, Michael Tanaka
Journal of Clinical Oncology. 2001-03-15

Abstracts/Posters

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed o...
Joseph Tuscano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Joseph Tuscano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase I Study of Escalating Doses of Carfilzomib with Hyper-CVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Joseph Tuscano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Blinatumomab/Lenalidomide in Relapsed/Refractory Non-HodgkinÍs Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis
Joseph Tuscano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Washington State Medical Oncology Society (WSMOS) 2013 Spring Oncology Conference
Washington State Medical Oncology Society (WSMOS), Seattle, Washington - 4/19/2013

Press Mentions

Sacramento Woman Celebrates 100th Clinical Trial Dose, Cancer-FreeNovember 15th, 2022
Eighth Annual Crush Challenge Bike Ride to Accelerate Cancer Research on Aug. 27August 5th, 2022
Oncternal Therapeutics : Lee 2022 ASCO Poster Zilovertamab + Ibrutinib for MCL and CLLJune 7th, 2022
Join now to see all